SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-051967
Filing Date
2021-04-19
Accepted
2021-04-19 16:15:21
Documents
6
Period of Report
2021-06-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2112429-1_def14a.htm DEF 14A 625339
2 GRAPHIC lg_kerostherapeutics-4clr.jpg GRAPHIC 19852
3 GRAPHIC sg_jasbirseehra-4c.jpg GRAPHIC 14569
4 GRAPHIC sg_esthercho-bw.jpg GRAPHIC 7054
5 GRAPHIC tm2112429d1-proxy_01pagebw.jpg GRAPHIC 658104
6 GRAPHIC tm2112429d1-proxy_02pagebw.jpg GRAPHIC 586098
  Complete submission text file 0001104659-21-051967.txt   2396308
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39264 | Film No.: 21834775
SIC: 2834 Pharmaceutical Preparations